20 (AIDX) Cost of Revenue (2025 - 2026)
20 (AIDX) posted Cost of Revenue of $290491.0 for Q1 2026, down 25.14% on a QoQ basis from $388025.0 in Q1 2025, and down 25.14% year-over-year from $388025.0 in Q1 2025.
20 (AIDX) Cost of Revenue (2025 - 2026) Analysis & Trends
20's Cost of Revenue history runs 2 years deep, the most recent figure standing at $290491.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.89 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 2.21 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 3.40 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 12.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 362.60 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 441.60 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 481.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 2.51 Bn |
| 10 | 20 | 3.46 Mn | -759,563.02 | 62,884.00 | 290,491.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 290,491.00 |
| Mar 31, 2026 | 290,491.00 |
| Mar 31, 2025 | 388,025.00 |
| Mar 31, 2025 | 388,025.00 |